Results of a recent study that used a new drug combination (glecaprevir/pibrentasivr) for chronic HCV and compensated cirrhosis of the liver, showed high virological cure rates.
The award will fund Dr. Guo's research into how hundreds of different bacterial species living in the human gut contribute to human health and disease.
This award is presented annually to members of the Weill Department of Medicine below the rank of professor who perform on outstanding levels in the areas of clinical and/or basic biomedical research.
This award was founded to encourage outstanding research in women’s health. The finalists presented their work at Medicine Grand Rounds.
Dr. Sharaiha will oversee a newly expanded interventional group, as well as advanced endoscopy training at the NewYork-Presbyterian's Greenberg Pavilion and David H. Koch Center.
Building upon the division’s strong legacy in the field of Inflammatory Bowel Disease (IBD), Dr. Longman will oversee and expand clinical, research and educational activities at the JRC.
The innate immune system is the body’s first line of defense against invading pathogens, but there has been a lack of information on what a “healthy” innate immune system looks like.
Dr. Guo’s lab will use a combination of bioinformatics, bacterial genetics, metabolomics, and mouse models to identify the molecular mechanisms behind host-microbiome interaction.
In his new role, Dr. Brown will continue to provide expertise as a Clinical Director while developing programs in faculty development across all of the department’s missions.
The project, set to begin in January 2018, is focused on determining whether the chemopreventive effects of the COX-2 inhibitor celecoxib are exerted, in part, through altering the intestinal microbiota and gut luminal metabolites.